Cariprazine 3 MG Oral Capsule — RxCUI 1667668
RxNorm drug concept · Semantic clinical drug
RxCUI 1667668
Semantic clinical drug · SCD
● Current RxNorm concept 7 FDA products
13 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI1667668
Official nameCariprazine 3 MG Oral Capsule
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped7
Package NDCs mapped13
Reported Medicaid activity (SDUD)1,076,596 prescriptions · 51 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Cariprazine: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Vraylar is used for a few different conditions depending on your age. For adults, it can treat schizophrenia, manic or mixed episodes of bipolar I disorder, the depressive episodes...
- This one takes some patience. Vraylar and its active breakdown products build up in your system slowly — it can take a week or two to start noticing changes, and full effects may n...
- How long does it take for Vraylar to start working?
- The most common things people notice are a feeling of restlessness or the urge to keep moving (called akathisia), stiffness or tremor in the muscles, nausea, constipation, or fatig...
🕸️ Concept Web — How Cariprazine 3 MG Oral Capsule Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Cariprazine 3 MG Oral Capsule
RxCUI 1667668 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Cariprazine
1667655IN
-
Cariprazine
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Vraylar
1667661BN
-
Vraylar
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Cariprazine Oral Capsule
1667659SCDF -
Cariprazine Oral Product
1667657SCDG -
Cariprazine Pill
1667658SCDG -
Cariprazine Oral Capsule [Vraylar]
1667663SBDF -
Vraylar Oral Product
1667664SBDG -
Vraylar Pill
1667665SBDG -
Oral Capsule
316965DF -
Oral Product
1151131DFG - +1 more in this family
-
Cariprazine Oral Capsule
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Cariprazine 3 MG
1667667SCDC -
Cariprazine 3 MG Oral Capsule [Vraylar]
1667670SBD -
Cariprazine 3 MG [Vraylar]
1667669SBDC
-
Cariprazine 3 MG
-
Packs 2
Fixed collections of drugs packaged and sold together, like dose packs.
Showing up to 8 concepts per family — 15 of 16 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
{1 (cariprazine 1.5 MG Oral Capsule) / 6 (cariprazine 3 MG Oral Capsule) } Pack
GPCK · 1741746 -
Cariprazine 3 MG
SCDC · 1667667 -
Cariprazine Oral Capsule
SCDF · 1667659 -
Cariprazine Oral Product
SCDG · 1667657 -
Cariprazine Pill
SCDG · 1667658
Brand-Name Concepts
-
Cariprazine 3 MG Oral Capsule [Vraylar]
SBD · 1667670 -
{1 (cariprazine 1.5 MG Oral Capsule [Vraylar]) / 6 (cariprazine 3 MG Oral Capsule [Vraylar]) } Pack [Vraylar 1.5/3 Mixed Pack]
BPCK · 1741747 -
Cariprazine 3 MG [Vraylar]
SBDC · 1667669 -
Cariprazine Oral Capsule [Vraylar]
SBDF · 1667663 -
Vraylar Oral Product
SBDG · 1667664 -
Vraylar Pill
SBDG · 1667665 -
Vraylar
BN · 1667661
📦 FDA Products & Package NDCs
7 products · 13 package NDCs
13 package NDCs map to RxCUI 1667668 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 61874-0115-07 | 7 CAPSULE, GELATIN COATED in 1 BLISTER PACK (61874-115-07) | Vraylar | Allergan, Inc. | 2016-03-01 |
| 61874-0115-17 | 1 BLISTER PACK in 1 CARTON (61874-115-17) / 7 CAPSULE, GELA... | Vraylar | Allergan, Inc. | 2016-03-01 |
| 61874-0115-20 | 2 BLISTER PACK in 1 CARTON (61874-115-20) / 10 CAPSULE, GEL... | Vraylar | Allergan, Inc. | 2016-03-01 |
| 61874-0115-30 | 30 CAPSULE, GELATIN COATED in 1 BOTTLE (61874-115-30) | Vraylar | Allergan, Inc. | 2016-03-01 |
| 61874-0130-07 | 7 CAPSULE, GELATIN COATED in 1 BLISTER PACK (61874-130-07) | Vraylar | Allergan, Inc. | 2016-03-01 |
| 61874-0130-20 | 2 BLISTER PACK in 1 CARTON (61874-130-20) / 10 CAPSULE, GEL... | Vraylar | Allergan, Inc. | 2016-03-01 |
| 61874-0130-30 | 30 CAPSULE, GELATIN COATED in 1 BOTTLE (61874-130-30) | Vraylar | Allergan, Inc. | 2016-03-01 |
| 61874-0145-07 | 7 CAPSULE, GELATIN COATED in 1 BLISTER PACK (61874-145-07) | Vraylar | Allergan, Inc. | 2016-03-01 |
| 61874-0145-30 | 30 CAPSULE, GELATIN COATED in 1 BOTTLE (61874-145-30) | Vraylar | Allergan, Inc. | 2016-03-01 |
| 61874-0160-07 | 7 CAPSULE, GELATIN COATED in 1 BLISTER PACK (61874-160-07) | Vraylar | Allergan, Inc. | 2016-03-01 |
| 61874-0160-30 | 30 CAPSULE, GELATIN COATED in 1 BOTTLE (61874-160-30) | Vraylar | Allergan, Inc. | 2016-03-01 |
| 61874-0250-30 | 30 CAPSULE, GELATIN COATED in 1 BOTTLE (61874-250-30) | Vraylar | Allergan, Inc. | 2025-12-18 |
| 61874-0275-30 | 30 CAPSULE, GELATIN COATED in 1 BOTTLE (61874-275-30) | Vraylar | Allergan, Inc. | 2025-12-18 |
Observed labelers:
Allergan, Inc. (13)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.